# Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00148291** · PHASE3 · COMPLETED · sponsor: **West Japan Thoracic Oncology Group** · enrollment: 180 (—)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.

## Key facts

- **NCT ID:** NCT00148291
- **Lead sponsor:** West Japan Thoracic Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 180 (—)
- **Last updated:** 2006-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148291, "Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00148291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*